Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arch Toxicol ; 95(12): 3787-3802, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34635930

RESUMEN

Nevadensin, an abundant polyphenol of basil, is reported to reduce alkenylbenzene DNA adduct formation. Furthermore, it has a wide spectrum of further pharmacological properties. The presented study focuses the impact of nevadensin on topoisomerases (TOPO) in vitro. Considering the DNA-intercalating properties of flavonoids, first, minor groove binding properties (IC50 = 31.63 µM), as well as DNA intercalation (IC50 = 296.91 µM) of nevadensin, was found. To determine potential in vitro effects on TOPO I and TOPO IIα, the relaxation and decatenation assay was performed in a concentration range of 1-500 µM nevadensin. A partial inhibition was detected for TOPO I at concentrations  ≥ 100 µM, whereas TOPO IIα activity is only inhibited at concentrations  ≥ 250 µM. To clarify the mode of action, the isolating in vivo complex of enzyme assay was carried out using human colon carcinoma HT29 cells. After 1 h of incubation, the amount of TOPO I linked to DNA was significantly increased by nevadensin (500 µM), why nevadensin was characterized as TOPO I poison. However, no effects on TOPO IIα were detected in the cellular test system. As a subsequent cellular response to TOPO I poisoning, a highly significant increase of DNA damage after 2 h and a decrease of cell viability after 48 h at the same concentration range were found. Furthermore, after 24 h of incubation a G2/M arrest was observed at concentrations ≥ 100 µM by flow cytometry. The analysis of cell death revealed that nevadensin induces the intrinsic apoptotic pathway via activation of caspase-9 and caspase-3. The results suggest that cell cycle disruption and apoptotic events play key roles in the cellular response to TOPO I poisoning caused by nevadensin in HT29 cells.


Asunto(s)
Apoptosis/efectos de los fármacos , Daño del ADN/efectos de los fármacos , ADN-Topoisomerasas de Tipo I/efectos de los fármacos , Flavonas/envenenamiento , Ciclo Celular/efectos de los fármacos , Neoplasias del Colon/enzimología , ADN-Topoisomerasas de Tipo II/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Flavonas/administración & dosificación , Células HT29 , Humanos , Concentración 50 Inhibidora , Proteínas de Unión a Poli-ADP-Ribosa/efectos de los fármacos , Factores de Tiempo
2.
Mol Biol Cell ; 32(21): ar18, 2021 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-34432484

RESUMEN

Stress granules (SGs) are ribonucleoprotein functional condensates that form under stress conditions in all eukaryotic cells. Although their stress-survival function is far from clear, SGs have been implicated in the regulation of many vital cellular pathways. Consequently, SG dysfunction is thought to be a mechanistic point of origin for many neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS). Additionally, SGs are thought to play a role in pathogenic pathways as diverse as viral infection and chemotherapy resistance. There is a growing consensus on the hypothesis that understanding the mechanistic regulation of SG physical properties is essential to understanding their function. Although the internal dynamics and condensation mechanisms of SGs have been broadly investigated, there have been fewer investigations into the timing of SG formation and clearance in live cells. Because the lifetime of SG persistence can be a key factor in their function and tendency toward pathological dysregulation, SG clearance mechanisms deserve particular attention. Here we show that resveratrol and its analogues piceatannol, pterostilbene, and 3,4,5,4'-tetramethoxystilbene induce G3BP-dependent SG formation with atypically rapid clearance kinetics. Resveratrol binds to G3BP, thereby reducing its protein-protein association valency. We suggest that altering G3BP valency is a pathway for the formation of uniquely transient SGs.


Asunto(s)
ADN Helicasas/metabolismo , Proteínas de Unión a Poli-ADP-Ribosa/metabolismo , ARN Helicasas/metabolismo , Proteínas con Motivos de Reconocimiento de ARN/metabolismo , Resveratrol/farmacología , Gránulos de Estrés/metabolismo , Proteínas Portadoras/metabolismo , Línea Celular Tumoral , Gránulos Citoplasmáticos/efectos de los fármacos , Gránulos Citoplasmáticos/metabolismo , ADN Helicasas/efectos de los fármacos , Células HEK293 , Células HeLa , Humanos , Cinética , Proteínas de Unión a Poli-ADP-Ribosa/efectos de los fármacos , ARN Helicasas/efectos de los fármacos , Proteínas con Motivos de Reconocimiento de ARN/efectos de los fármacos , Ribonucleoproteínas/metabolismo , Gránulos de Estrés/efectos de los fármacos
3.
Cell Death Dis ; 12(6): 530, 2021 05 24.
Artículo en Inglés | MEDLINE | ID: mdl-34031359

RESUMEN

Non-coding RNA from pericentromeric satellite repeats are involved in stress-dependent splicing processes, maintenance of heterochromatin, and are required to protect genome stability. Here we show that the long non-coding satellite III RNA (SatIII) generates resistance against the topoisomerase IIa (TOP2A) inhibitor etoposide in lung cancer. Because heat shock conditions (HS) protect cells against the toxicity of etoposide, and SatIII is significantly induced under HS, we hypothesized that the protective effect could be traced back to SatIII. Using genome methylation profiles of patient-derived xenograft mouse models we show that the epigenetic modification of the SatIII DNA locus and the resulting SatIII expression predict chemotherapy resistance. In response to stress, SatIII recruits TOP2A to nuclear stress bodies, which protects TOP2A from a complex formation with etoposide and results in decreased DNA damage after treatment. We show that BRD4 inhibitors reduce the expression of SatIII, restoring etoposide sensitivity.


Asunto(s)
Resistencia a Antineoplásicos/genética , Etopósido/uso terapéutico , ARN Largo no Codificante/fisiología , Animales , Antineoplásicos/farmacología , Proteínas de Ciclo Celular/antagonistas & inhibidores , Centrómero/genética , Centrómero/metabolismo , Metilación de ADN/fisiología , ADN-Topoisomerasas de Tipo II/efectos de los fármacos , ADN-Topoisomerasas de Tipo II/genética , ADN-Topoisomerasas de Tipo II/metabolismo , Resistencia a Antineoplásicos/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Células HEK293 , Células HeLa , Humanos , Masculino , Ratones Endogámicos NOD , Ratones SCID , Proteínas de Unión a Poli-ADP-Ribosa/efectos de los fármacos , Proteínas de Unión a Poli-ADP-Ribosa/genética , Proteínas de Unión a Poli-ADP-Ribosa/metabolismo , ARN Largo no Codificante/genética , Factores de Transcripción/antagonistas & inhibidores , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
4.
Biomed Res Int ; 2019: 2514524, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31815127

RESUMEN

A- and D-ring-modified luotonin-inspired heterocycles have been synthesized and were evaluated for their activity against the viability of four cancer cell lines in vitro, namely, MCF7, HCT116, JURKAT, and NCI-H460. The analysis of results indicated that two of the synthesized derivatives displayed good inhibition against the growth of the human colon cancer HCT116 cell line, with potencies lower than but in the same order of magnitude as camptothecin (CPT). These two luotonin analogues also showed an activity similar to that of the highly potent alkaloid CPT as inhibitors of topoisomerase I and also inhibited topoisomerase II. These results show that complete planarity is not a strict requirement for topoisomerase inhibition by luotonin-related compounds, paving the way to the design of analogues with improved solubility.


Asunto(s)
Antineoplásicos/farmacología , ADN-Topoisomerasas de Tipo II/efectos de los fármacos , ADN-Topoisomerasas de Tipo I/efectos de los fármacos , Proteínas de Unión a Poli-ADP-Ribosa/efectos de los fármacos , Pirroles/síntesis química , Pirroles/farmacología , Quinonas/síntesis química , Quinonas/farmacología , Inhibidores de Topoisomerasa/farmacología , Alcaloides/farmacología , Camptotecina/análogos & derivados , Camptotecina/síntesis química , Línea Celular Tumoral/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Humanos , Simulación del Acoplamiento Molecular , Solubilidad , Relación Estructura-Actividad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...